In Vitro and in Vivo Pharmacological Characterization of the Neuropeptide S Receptor Antagonist [d-Cys(tBu)5]Neuropeptide S
- 1 February 2009
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 328 (2) , 549-555
- https://doi.org/10.1124/jpet.108.143867
Abstract
Neuropeptide S (NPS) was identified as the endogenous ligand of an orphan receptor now referred to as the NPS receptor (NPSR). In the frame of a structure-activity study performed on NPS Gly5, the NPSR ligand [d-Cys(tBu)5]NPS was identified. [d-Cys(tBu)5]NPS up to 100 μM did not stimulate calcium mobilization in human embryonic kidney (HEK) 293 cells stably expressing the mouse NPSR; however, in a concentration-dependent manner, the peptide inhibited the stimulatory effects elicited by 10 and 100 nM NPS (pKB, 6.62). In Schild analysis experiments [d-Cys(tBu)5]NPS (0.1–100 μM) produced a concentration-dependent and parallel rightward shift of the concentration-response curve to NPS, showing a pA2 value of 6.44. Ten micromolar [d-Cys(tBu)5]NPS did not affect signaling at seven NPSR unrelated G-protein-coupled receptors. In the mouse righting reflex (RR) recovery test, NPS given at 0.1 nmol i.c.v. reduced the percentage of animals losing the RR in response to 15 mg/kg diazepam and their sleeping time. [d-Cys(tBu)5]NPS (1–10 nmol) was inactive per se but dose-dependently antagonized the arousal-promoting action of NPS. Finally, NPSR-deficient mice were similarly sensitive to the hypnotic effects of diazepam as their wild-type littermates. However, the arousal-promoting action of 1 nmol NPS could be detected in wild-type but not in mutant mice. In conclusion, [d-Cys(tBu)5]NPS behaves both in vitro and in vivo as a pure and selective NPSR antagonist but with moderate potency. Moreover, using this tool together with receptor knockout mice studies, we demonstrated that the arousal-promoting action of NPS is because of the selective activation of the NPSR protein.Keywords
This publication has 27 references indexed in Scilit:
- Neuropeptide S-Mediated Control of Fear Expression and Extinction: Role of Intercalated GABAergic Neurons in the AmygdalaNeuron, 2008
- Synthesis and Pharmacological in Vitro and in Vivo Profile of 3-Oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic Acid 4-Fluoro-benzylamide (SHA 68), a Selective Antagonist of the Neuropeptide S ReceptorThe Journal of Pharmacology and Experimental Therapeutics, 2008
- Neuropeptide S is a stimulatory anxiolytic agent: a behavioural study in miceBritish Journal of Pharmacology, 2008
- An essential role for orexins in emergence from general anesthesiaProceedings of the National Academy of Sciences, 2008
- Phylogenetic appearance of neuropeptide S precursor proteins in tetrapodsPeptides, 2007
- Distribution of neuropeptide S receptor mRNA and neurochemical characteristics of neuropeptide S‐expressing neurons in the rat brainJournal of Comparative Neurology, 2006
- Pharmacological Characterization of Human and Murine Neuropeptide S Receptor VariantsThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Peptide S is a novel potent inhibitor of voluntary and fast-induced food intake in ratsBiochemical and Biophysical Research Communications, 2005
- International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative PharmacologyPharmacological Reviews, 2003
- Intracerebroventricular injections in miceJournal of Pharmacological Methods, 1986